Skip to main content
SpringerLink
Log in

Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Our aim is to investigate visfatin concentration and its relationship to glycated hemoglobin (HbA1c), insulin resistance, lipid parameters, and neonatal birth weight in women with gestational diabetes mellitus (GDM). In our study group, there were 47 women with GDM and 31 women with normal glucose tolerance (NGT) between 33–39 weeks of gestation. Plasma visfatin levels were significantly decreased in pregnant women with GDM compared to those with NGT (p=0.001). Homeostasis model assessment-insulin resistance (HOMA-IR) levels were higher in the GDM group than in the NGT group (p=0.006). In all subjects, plasma visfatin levels were negatively correlated with HOMA-IR, post-prandial blood glucose, triglycerides, and VLDL cholesterol (p<0.05). We did not observe any statistically significant correlation between the plasma visfatin levels and the selected parameters in the GDM group, but in the NGT group plasma visfatin levels were negatively correlated with HOMA-IR (r=-0.36, p=0.04). There was no correlation between visfatin concentrations and fetal birth weight in either group (p>0.05). By regression analysis, having GDM was found to be the only significant determinant (t=3.5, p=0.001) of visfatin concentration (R=0.39, r2=0.15). We conclude that women with GDM have significantly decreased visfatin concentrations in the third trimester. Future studies are required to establish the exact role of visfatin in the pathogenesis of GDM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pilz S, Mangge H, Obermayer-Pietsch B, März W. Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions. J Endocrinol Invest 2007, 30: 138–44.

    Article  PubMed  CAS  Google Scholar 

  2. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007, 56: 565–70.

    Article  PubMed  CAS  Google Scholar 

  3. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006, 49: 1909–14.

    Article  PubMed  CAS  Google Scholar 

  4. Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006, 91: 295–9.

    Article  PubMed  CAS  Google Scholar 

  5. López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006, 55: 2871–5.

    Article  PubMed  CAS  Google Scholar 

  6. Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006, 114: 544–8.

    Article  PubMed  CAS  Google Scholar 

  7. Kautzky-Willer A, Bancher-Todesca D. Endocrine changes in diabetic pregnancy. In: Djelmiš J, Desoye G, Ivanišević: M eds. Diabetology of pregnancy. Frontiers in diabetes. Vol. 17. Basel: Karger 2005, 18–33.

    Chapter  Google Scholar 

  8. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2004, 27(suppl 1): S88–90.

    Google Scholar 

  9. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest 2005, 115: 485–91.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  10. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002, 25: 1862–8.

    Article  PubMed  Google Scholar 

  11. Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 2006, 110: 605–9.

    Article  CAS  Google Scholar 

  12. Lewandowski KC, Stojanovic N, Press M, et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 2007, 50: 1033–7.

    Article  PubMed  CAS  Google Scholar 

  13. Chan TF, Chen YL, Lee CH, et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig 2006, 13: 364–7.

    Article  PubMed  CAS  Google Scholar 

  14. Haider DG, Handisurya A, Storka A, et al. Visfatin response to glucose is reduced in women with gestational diabetes mellitus. Diabetes Care 2007, 30: 1889–91.

    Article  PubMed  CAS  Google Scholar 

  15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.

    Article  PubMed  CAS  Google Scholar 

  16. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006, 91: 1578–81.

    Article  PubMed  CAS  Google Scholar 

  17. Krzyzanowska K, Mittermayer F, Krugluger W, Kopp HP, Schernthaner G. Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity (Silver Spring) 2006, 14: 1886–9.

    Article  CAS  Google Scholar 

  18. Ognjanovic S, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gynecol 2002, 187: 1051–8.

    Article  PubMed  CAS  Google Scholar 

  19. Malamitsi-Puchner A, Briana DD, Gourgiotis D, Boutsikou M, Baka S, Hassiakos D. Blood visfatin concentrations in normal full-term pregnancies. Acta Paediatr 2007, 96: 526–9.

    Article  PubMed  Google Scholar 

  20. Malamitsi-Puchner A, Briana DD, Boutsikou M, Kouskouni E, Hassiakos D, Gourgiotis D. Perinatal circulating visfatin levels in intrauterine growth restriction. Pediatrics 2007, 119: e1314–8.

    Article  PubMed  Google Scholar 

  21. Kuhl C. Etiology and pathogenesis of gestational diabetes. Diabetes Care 1998, 21(Suppl 2): B19–26.

    PubMed  Google Scholar 

  22. Kinoshita T, Itoh M. Longitudinal variance of fat mass deposition during pregnancy evaluated by ultrasonography: the ratio of visceral fat to subcutaneous fat in the abdomen. Gynecol Obstet Invest 2006, 61: 115–8.

    Article  PubMed  Google Scholar 

  23. Lim S, Choi SH, Park YJ, et al. Visceral fatness and insulin sensitivity in women with a previous history of gestational diabetes mellitus. Diabetes Care 2007, 30: 348–53.

    Article  PubMed  Google Scholar 

  24. Mastorakos G, Valsamakis G, Papatheodorou DC, et al. The role of adipocytokines in insulin resistance in normal pregnancy: visfatin concentrations in early pregnancy predict insulin sensitivity. Clin Chem 2007, 53: 1477–83.

    Article  PubMed  CAS  Google Scholar 

  25. Fasshauer M, Blüher M, Stumvoll M, Tönessen P, Faber R, Stepan H. Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. Clin Endocrinol (Oxf) 2007, 66: 434–9.

    Article  CAS  Google Scholar 

  26. Wang P, van Greevenbroek MM, Bouwman FG, et al. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch 2007, 454: 971–6.

    Article  PubMed  CAS  Google Scholar 

  27. López-Bermejo A, Fernandez-Real JM, Garrido E, et al. Maternal soluble tumour necrosis factor receptor type 2 (sTNFR2) and adiponectin are both related to blood pressure during gestation and infant’s birthweight. Clin Endocrinol (Oxf) 2004, 61: 544–52.

    Article  CAS  Google Scholar 

  28. Briana DD, Boutsikou M, Gourgiotis D, et al. Role of visfatin, insulin-like growth factor-I and insulin in fetal growth. J Perinat Med 2007, 35: 326–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, Faculty of Medicine, Gazi University, Turkey

    M. Akturk & M. Arslan

  2. Division of Endocrinology, Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, Turkey

    A. E. Altinova

  3. Department of Obstetrics and Gynecology, Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, Turkey

    I. Mert, A. Sargin & N. Danisman

  4. Division of Biochemistry, Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, Turkey

    U. Buyukkagnici

Authors
  1. M. Akturk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. E. Altinova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Mert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Buyukkagnici
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Sargin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Arslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N. Danisman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Akturk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Akturk, M., Altinova, A.E., Mert, I. et al. Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester. J Endocrinol Invest 31, 610–613 (2008). https://doi.org/10.1007/BF03345611

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345611

Key-words

Search

Navigation